A clinical study showed a reduction of alternating constipation and diarrhea for the participants taking DE111 (1 billion CFU) when compared to participants taking the placebo. The proportion of normal stools (types 3 and 4) increased from 54% to 64% in the DE111 group, while the proportion of normal stools decreased from 56% to 48% in the placebo group. In male participants specifically, the proportion of normal stools increased from 56% to 80%. In addition, a significant difference between the DE111 and placebo groups was observed in regards to normal and non-normal stool proportions in the 30+ age group.
KENNESAW, GA (August 2, 2021) - Deerland Probiotics & Enzymes has announced the publication of a new study that is…More
Delicious dark chocolate is a sweet delivery system for probiotics, and combining the two delivers a bounty of healthy benefits.…More
KENNESAW, Ga. (June 29, 2021) – It’s no secret: probiotics are in demand across many health and wellness categories. For themselves…More